ArticlebioRxiv : the preprint server for biology2025
Controlled Release of Poly(U) via Acetalated Dextran Microparticles for Enhanced Vaccine Adjuvant Delivery.
Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Diverse drug delivery systems are needed to address challenges in delivering novel vaccine components and enhancing their efficacy. Poly(U) is a single-stranded RNA composed of uracil repeats that acts as a toll-like receptor (TLR) 7/8 agonist, stimulating the innate immune system. However, poly(U) is susceptible to ribonuclease degradation without a delivery carrier, and its negative charge hinders cellular uptake. Encapsulation in acetalated dextran (Ace-DEX), a pH-sensitive, biodegradable polymer, addresses these challenges. This study encapsulated poly(U) into Ace-DEX Microparticles (MPs) with either spherical (smooth MPs) or collapsed-surface (wrinkled MPs) via spray-drying. It was hypothesized that the different morphologies of MPs would influence the vaccine efficacy after in vitro and in vivo models. Smooth poly(U) MPs had a higher percent viability and cytokine response in dendritic cells (DCs) than wrinkled poly(U) MPs. Moreover, mice vaccinated with smooth poly(U) MPs + ovalbumin (OVA) showed enhanced IL-2 production and IFN-γ in response to OVA peptide and MHC-I immunodominant peptide restimulation, respectively, compared to wrinkled poly(U) MPs. However, mice vaccinated with wrinkled poly(U) MPs + OVA significantly increased B-cell and germinal center B-cell frequencies compared to mice vaccinated with phosphate buffered saline (PBS) whereas mice vaccinated with smooth poly(U) MPs + OVA did not. Overall, these findings suggest that smooth poly(U) MPs modulated dendritic cells and T-cells, and wrinkled poly(U) MPs modulated B-cells. Understanding how morphology influences these cell types will aid in optimizing future vaccine systems for more specific cellular targeting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.